Browsing: Wins

Every antidepressant approved by the FDA — from Prozac to esketamine to the new wave of psychedelic-derived compounds advancing through late-stage trials — acts inside the brain. SSRIs rebalance serotonin at synapses. NMDA antagonists modulate glutamate. Psilocybin remodels neural plasticity. The assumption built into all of them is that depression is, at root, a disorder…

Researchers at Gazipur Agricultural University (GAU) have secured a patent for a technology that converts jackfruit seeds into a concentrated mineral-rich food ingredient, an innovation that could help improve nutrition and reduce food waste

Strange Health, a video podcast produced by The Conversation UK, has won the best health and wellbeing award at the Publisher Podcast Awards 2026

The Door has been named agency of record for Palm Tree Crew, expanding its roster of lifestyle and entertainment clients as the brand founded by music producer Kygo and entrepreneur Myles Shear accelerates its growth beyond live events into hospitality, real estate, golf and consumer ventures

Swan Hill Rural City Council has secured funding through VicHealth’s Partners in Place program, unlocking an exciting opportunity to deliver locally led initiatives that improve the health and wellbeing of communities across the region

Find your next quality investment with Simply Wall St’s easy and powerful screener, trusted by over 7 million individual investors worldwide

July 15 (Reuters) – Novo Nordisk said on Wednesday the European Commission approved its once-daily Wegovy pill for weight management in adults with obesity or who are overweight, making it the first oral GLP-1 weight-loss treatment cleared for use across the European Union

A group of Indiana research and business organizations led by Indiana University faculty is receiving funds from the National Science Foundation to build a musculoskeletal health research hub

D&D Pharmatech (347850.KQ) has expanded its joint research collaboration with U.S. pharmaceutical company Pfizer on an obesity treatment. Following an additional order from Pfizer, the value of the research service contract has increased 38% from the previous level, and the contract term has been extended until 2028